Bacteriologic profile, antibiotics resistance pattern, and outcomes of patients admitted to Lancet General Hospital from June 2022 to June 2023: A retrospective cohort study

Background Prior studies indicated increased antimicrobial resistance in Ethiopia, with related health, economic, and environmental costs. Knowing an institutions and population microbiologic profile allows for proper antibi-otic treatment, which substantially impact patients' outcomes such as healthcare related costs, morbidity, and mortality. The current study assessed the bacteriologic profile, resistance pattern, and treatment outcome in Lancet General Hospital. Method A retrospective cohort study on the bacteriologic profile, antibiotics resistance pattern, and outcome of patients was done on 128 eligible patients who were admitted to Lancet General Hospital from June 2022 to June 2023. Data from all hospitalized patients with culture-confirmed infection were analyzed. SPSS version 26.0 was used to analyze the data. Association between independent and dependent variables was analyzed using binary logistic regression model. Results Gram-negative bacteria were recovered in 77% of the cases. Extended-spectrum beta-lactamase producing Enterobacteriaceae was found in 37.5% (54) isolates and carbapenem resistant bacteria were identified in 27.8% of patients. In-hospital mortality from multidrug resistant bacterial infection was 14.8%. Age ≥ 65 years, presence of septic shock, and presence of carbapenem-resistant bacteria were independently associated with in-creased in-hospital mortality. Conclusion High number of resistant microorganisms was isolated, and increased mortality was documented from infections caused by carbapenem-resistant bacteria. Multi-center studies should be done to determine the extent of resistant organisms in health facilities throughout the country. epidemiology, and the findings should be factored into clinical decision making and program design for disease prevention, screening, and treatment. It also calls for further prospective research to learn more about the conditions in the context of additional relevant personal and clinical characteristics

Extended-Spectrum Beta-lactamase and Metallo-beta-lactamase Production among Escherichia coli and Klebsiella pneumoniae Strains from Urine of Pregnant Women in Afikpo, Ebonyi State, Nigeria

Aim: The aim of this study was to determine the occurrence of Extended-spectrum beta-lactamase (ESBL) and Metallo-beta-lactamase (MBL) among Escherichia coli and Klebsiella pneumoniae strains from pregnant women attending Mater Misericordia Hospital Afikpo, Ebonyi state, Nigeria. Study Design: This is a laboratory based prospective study carried out on pregnant women suspected of having urinary tract infection and was requested to undergo diagnosis at microbiology laboratory of the hospital. Place and Duration of Study: The study was conducted in the Department of Science Laboratory Technology, Akanu Ibiam Federal Polytechnic, Unwana, Afikpo, Ebonyi State, Nigeria from October, 2022 to January, 2023. Methodology: Clean-catch midstream urine samples were collected from 206 pregnant women suspected of having urinary tract infection and were requested to undergo medical diagnosis at microbiology laboratory of the hospital. The urine samples were processed following standard microbiological procedure. Antimicrobial susceptibility testing was determined using the disc diffusion method, while ESBL phenotypes were determine by the Double-Disc Synergy Test (DDST). Disc potentiation test was performed to check for MBL production. Results: Out of the 206 urine samples processed, 24 (11.7 %) E. coli and 12 (5.8 %) K. pneumoniae were isolated. The antimicrobial susceptibility of the isolates recorded a 100 % resistance with Amoxicillin/Clavulanic acid and Cotrimoxazole. The Gram-negative isolates showed a high sensitivity of 100 % to Netilmicin, Meropenem and Ofloxacin. Overall, 35 (97.2 %) multidrug resistance (MDR) was observed of the bacteria isolates. A total of 9 (37.5 %) E. coli and 4 (33.3 %) K. pneumoniae was found positive for ESBL production whereas, 5 (20.8 %) E. coli and 2 (16.7 %) K. pneumoniae were MBL positive. Conclusion: The level of drug resistance in this study underscores the need for regular surveillance for effective management of urinary tract infection in pregnancy.

Risk factors for extended-spectrum beta-lactamase- and carbapenem- resistant Enterobacteriaceae in patients with urinary tract infection from a tertiary care hospital

Background: Urinary tract infection (UTI) is a common health problem in both community and nosocomial settings. However, the predisposing factors which are responsible for production of extended spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobacteriaceae makes the treatment option narrow and cause multidrug resistance. Aim and Objectives: This study demonstrate various risk factors associated with multidrug resistance in Enterobacteriaceae from UTI at tertiary care center in Gujarat. Material and Methods: A retrospective observational study was conducted at a tertiary-care hospital. Urine samples were received from various departments and outpatient department (OPD). Organisms from Enterobacteriaceae group were isolated and identified by various biochemical methods. ESBL and Carbapenemase producing organisms were then processed for Antibiotic susceptibility test as per CLSI guideline. Results: A total of 196 Enterobacteriaceae organisms were isolated from processed urine samples of tertiary care Hospitals. The most prevalent in people aged 45–65 years (36%) followed by those aged 17–30 (22%) years. UTI due to ESBL and Carbapenemase producer are more isolated in female (28%, 11%) as compare to male (16%, 6%). Indoor patients had higher prevalence of ESBL (29%) and carbapenemases (10%) isolation compare to OPD patient (ESBL-15%, Carbapenemases-7%) and among them most common ward was medicine department. The most common predisposing factor was catheterization followed by diabetes mellitus and obstructive uropathy. Conclusion: High prevalence of ESBL and Carbapenemase producing Enterobacteriaceae is found in Indoor patients than OPD patients. Most of these patients are from Medicine department. Catheterization is the most common risk factor associated with ESBL and carbapenemase producing organism.

Detection and prevalence of extended spectrum ?-lactamases in gram-negative bacteria at our health-care center

Background: Emergence of extended spectrum ?-lactamase (ESBL) producing strains of Gram-negative bacteria can lead to serious infections frequently complicates the clinical and treatment outcome. Aims and Objectives: The purpose of this study was to know the prevalence of ESBLs and to know the most common Gram-negative bacteria, which produce ESBLs at our health-care facility. Materials and Methods: This study comprised all of the isolates of Gram-negative bacteria that were acquired from various clinical samples. For the purpose of the investigation, a sample of an isolate that showed resistance to two or more third-generation cephalosporins was taken. ESBL detection and antibiotic sensitivity tests were carried out using conventional microbiological techniques. Results: We isolated a total of 284 Gram-negative bacteria and 54 (19%) were identified as ESBL producers. Out 54 ESBL producers, 18 (33%) isolates were Escherichia coli, 11 (20%) were Pseudomonas aeruginosa, 12 (22%) were Klebsiellae, 6 (11%) were Enterobacter, 2 (4%) were Citrobacter, 4 (8%) were Acinetobacter, and 1 (2%) were Serratia spp. Conclusion: Clinical decision-makers can make the best antibiotic treatment by regularly monitoring multi-drug resistant bacteria like ESBL producers. This also helps to improve infection control procedures. In addition, we must maintain reserve medications like carbapenems on hand for judicial use.

Detection and correlation of antimicrobial resistance pattern in Enterobacteriaceae from UTI patients in GMERS Medical College, Gujarat

Background: Bacterial resistance to antibiotics is a growing public health threat worldwide. The increasing rate of antimicrobial resistance among bacterial pathogens causing both hospital- and community-acquired infections is a serious threat to public health world-wide. This inappropriate and non-judicious usage of antibiotics has resulted in the development of worldwide antibiotic resistance in bacteria, leading to the emergence of multi-resistant strains of bacterial pathogens. This study focuses on the prevalence of antibiotic resistance in the Enterobacteriaceae group of organisms in urine samples and also detects various methods of antibiotic resistance. Antibiotic resistance detection may be useful for epidemiological and research purposes, as well as for preventing the spread of drug-resistant organisms within hospitals through good infection control practices. Aims and Objectives: The aim of the study was to detect occurrence of ?-lactamases, extended-spectrum beta-lactamases (ESBL) and Carbapenemase by phenotypic methods in Enterobacteriaceae from urine samples along with pattern of antibiotic resistance for various antibiotics in them. Materials and Methods: A descriptive study was conducted at a tertiary-care hospital. Testing of ESBL and carbapenemase production detection done according to CLSI (M100) guideline by the Kirby-Bauer disk diffusion method, combination disc diffusion test, and modified Carbapenem inactivation method. Results: A total of 220 Enterobacteriaceae organisms were isolated from processed urine samples of tertiary care Hospitals. Rate of cephalosporin resistance in ESBL and carbapenem-resistant Enterobacteriaceae (CRE) is more than 90% while in non-ESBL more than 70% and in non-CRE 75–80%. Carbapenem resistance in ESBL and non-ESBL is the same. Resistance to fluoroquinolone group, Aminoglycoside group, and Cotrimoxazole and Tetracycline group of antibiotics were more noticed in ESBL and carbapenemase producing organisms. In our study, fosfomycin and Nitrofurantoin are effective treatment in case of ESBL and CRE producing organism. Conclusion: The ESBL and Carbapenemase producing isolates were multi-drug resistant making therapeutic choices limited. Fosfomycin and Nitrofurantoin are effective treatment in multidrug resistance urinary tract infection.

Characterization of third generation cephalosporin-resistant Escherichia coli clinical isolates from Ushuaia, Argentina / Caracterización de aislamientos clínicos de Escherichia coli resistente a cefalosporinas de tercera generación de Ushuaia, Argentina

Abstract Escherichia coli is one of the main human pathogens causing different hospital- and community-acquired infections. During the period from January 2013 to March 2015, 1.96% (32/1632) of E. coli isolates recovered at the Hospital Regional de Ushuaia, Tierra del Fuego province, were resistant to third-generation cephalosporins (TGCs). These isolates were resistant to cefotaxime (91%) and/or ceftazidime (28%). No resistance to carbapenems was detected. Twenty-six isolates were positive for blaCTX-M gene, grouped as CTX-M-1/15 (54%); CTX-M-9/14 (25%); CTX-M-2 (17%); and CTX-M-1/15 plus CTX-M-9/14 (4%). Five TGC-resistant strains were positive for blaCMY gene, while one strain harbored TEM-19 ESBL. Twelve isolates were identified as ST131 E. coli hyperepidemic clone, and one as ST69. Genome sequence analysis of seven blaCTX-M-15 E. coli selected isolates confirm the circulation of ST131, ST617 and ST405 international high-risk clones in the city of Ushuaia.

Resumen Escherichia coli es uno de los principales patógenos humanos causantes de diferentes infecciones de inicio hospitalario y comunitario. Se determinó que el 1,96% (32/1.632) de los aislamientos de E. coli recuperados entre enero de 2013 y marzo de 2015 en el Hospital Regional de Ushuaia, provincia de Tierra del Fuego, fueron resistentes a cefalosporinas de tercera generación (CTG). Estos aislamientos fueron resistentes a cefotaxima (91%) y/o a ceftazidima (28%). No se detectó resistencia a los carbapenemes. Veintiséis aislamientos fueron positivos para el gen blaCTX-M, agrupados como CTX-M-1/15 (54%), CTX-M-9/14 (25%), CTX-M-2 (17%) y CTX-M-1/15 más CTX-M-9/14 (4%). Cinco cepas resistentes a CTG dieron positivo para el gen blaCMY, mientras que un aislamiento presentó la BLEE TEM-19. Doce aislamientos se identificaron como clon hiperepidémico E. coli ST131 y uno como ST69. El análisis de las secuencias del genoma de siete aislamientos seleccionados de E. coli blaCTX-M-15 confirmó la circulación de los clones internacionales de alto riesgo ST131, ST617 y ST405 en la ciudad de Ushuaia.

Resistencia antibiótica de Escherichia coli, según producción de beta lactamasas de espectro extendido, en urocultivos. Hospital III-1. Chiclayo, Perú 2020

Objetivo: determinar la resistencia antibiótica de Echerichia coli, en urocultivos, según produccion de BLEE, en pacientes hospitalizados. El estudio: Diseño descriptivo - retrospectivo. La identificación bacteriana se hizo con VITEK XL, la susceptibilidad, con las pautas del CLSI M100. 30 edicion. Hallazgos. E. coli BLEE positivo, presento resistencia de 0% a: Meropenem, ertapenem, tigeciclina y colistina. Piperacilina/tazobactam, nitrofurantoina, imipenem, amicacina con 16.7%, 6.2%, 5% y 1% respectivamente. E. Coli BLEE negativo, presento resistencia de 0% a: cefotaxima, cefuroxime, tigeciclina y piperacilina/tazobactam. Ceftriaxona, cefepime, gentamicina, cefazolina, ceftazidima, nitrofurantoina, meropenem, amicacina, imipenem y ertapenem con 14.7%, 13%, 13%, 10.7%, 9.7%, 9.1%, 9.1%, 8%, 5%, 2.7%, respectivamente. Conclusion: Meropenen, ertapenem, tigeciclina, colestina, piperacilina/tazobactam, nitrofurantoina, amicacina y imipenem, con resistencia menor de 20%, fueron los mismos, para E. coli BLEE positivo, y E. coli, sin considerar la produccion de BLEE.

ABSTRAC Objective: to determine the antibiotic resistance of Echerichia coli, in urine cultures, according to ESBL production, in hospitalized patients. The study: Descriptive-retrospective design. Bacterial identification was done with VITEK XL, susceptibility, with the CLSI M100 guidelines. 30 edition. Findings: E. coli ESBL positive, presented 0% resistance to: Meropenem, ertapenem, tigecycline and colistin. Piperacillin/tazobactam, nitrofurantoin, imipenem, amikacin with 16.7%, 6.2%, 5% and 1% respectively. E. Coli ESBL negative, presented 0% resistance to: cefotaxime, cefuroxime, tigecycline and piperacillin/tazobactam. Ceftriaxone, cefepime, gentamicin, cefazolin, ceftazidime, nitrofurantoin, meropenem, amikacin, imipenem, and ertapenem with 14.7%, 13%, 13%, 10.7%, 9.7%, 9.1%, 9.1%, 8%, 5%, 2.7%, respectively. Conclusion: Meropenen, ertapenem, tigecycline, cholesterol, piperacillin/tazobactam, nitrofurantoin, amikacin and imipenem, with less than 20% resistance, were the same for ESBL-positive E. coli, and E. coli, without considering ESBL production.

Impacto de infecciones y enterobacterias productoras de betalactamasa de espectro extendido en la supervivencia del injerto y del paciente en un programa de trasplante renal en México / Impact of infections and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on graft and patient survival in a kidney transplantation program in Mexico

Resumen Introducción: Los tratamientos inmunosupresores han mejorado las tasas de supervivencia del injerto y del paciente, pero pueden incrementar las infecciones postrasplante. Objetivos: Analizar los datos de pacientes con trasplante renal y describir las bacterias responsables de las infecciones que presentan. Métodos: Estudio observacional, longitudinal y analítico de 103 pacientes sometidos a trasplante renal. El periodo de seguimiento fue de 5.07 ± 1.28 años. Resultados: La tasa de mortalidad fue de 10.68 % y la de pérdida del injerto de 14.56 %. Respecto al riesgo de muerte del receptor, el modelo de regresión de Cox mostró un cociente de riesgo (HR, hazard ratio) de 5.66 en los pacientes con cultivo bacteriano positivo y de 2.22 en aquellos con cepas productoras de betalactamasas de espectro extendido (BLEE); en cuanto a la pérdida del injerto, el HR fue de 4.59 en quienes tuvieron cultivo bacteriano positivo y de 4.25 en aquellos con cepas productoras de BLEE. Conclusiones: Se encontró riesgo significativo de muerte en receptores de trasplante renal con cultivo bacteriano positivo y mayor riesgo de pérdida del injerto en aquellos con cultivo bacteriano positivo y aislamiento de cepas productoras de BLEE. La tasa de enterobacterias productoras de BLEE es alta, por ello son necesarias estrategias más estrictas para controlar del uso de antibióticos.

Abstract Introduction: Immunosuppressive treatments have improved graft and patient survival rates, but can increase the incidence of post-transplant infections. Objectives: To analyze data from kidney transplant patients and describe the pathogens responsible for the infections they experience. Methods: Longitudinal, analytical, observational study of 103 patients who underwent kidney transplantation. The follow-up period was 5.07 ± 1.28 years. Results: Overall mortality rate was 10.68% and graft loss rate was 14.56%. Regarding recipient risk of death, the Cox regression model showed a hazard ratio (HR) of 5.66 for positive bacterial cultures and 2.22 for positive extended-spectrum beta-lactamase (ESBL)-producing strains; as for graft loss, HR was 4.59 in those with positive bacterial cultures and 4.25 in those who were positive for ESBL-producing strains Conclusions: Significant death risk was found in kidney transplant recipients with positive bacterial cultures and an increased risk of graft loss in those with positive bacterial cultures and in those who were positive for ESBL-producing Enterobacteriaceae isolates. The rate of ESBL-producing Enterobacteriaceae is high, and stricter strategies are therefore necessary to control the use of antibiotics.

Risk factors for ESBL-positive Escherichia coli urinary tract infections / Factores de riesgo para infección urinaria por Escherichia coli BLEE positiva

Abstract Objective: to determine the association of prior antibiotic use, prior hospitalizations, prior urinary tract infections, age, sex and comorbidities in adult patients hospitalized with urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Materials and methods: a case-control study carried out in the hospital setting of private clinics in Lima. Thirty cases and 30 controls were included, with cases defined as hospitalized patients with an ESBL-producing E. coli urinary tract infection diagnosed by urine culture, and controls defined as hospitalized patients without ESBL-producing E. coli infection. Data were taken from incident cases. A bivariate analysis was performed followed by multivariate logistic regression using the significant variables from the bivariate analysis. Results: the associated factors were: prior antibiotic use OR: 261 (22.5-11,017.4), prior hospitalization OR: 4.6 (1.39-16.1), and prior urinary tract infection OR: 36 (6.9-227.2). After adjusting for potential confounding factors using logistic regression, the main statistically significant associated factor was prior antibiotic use, OR: 97.7 (8.4-1,128.3, p<0.000). Conclusion: evidence was found that prior antibiotic use is a risk factor significantly associated with ESBL E. coli urinary tract infections. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2131).

Resumen Objetivo: establecer la asociación del uso previo de antibióticos, hospitalizaciones previas, infección urinaria previa, edad, sexo y comorbilidades en pacientes adultos hospitalizados con infección urinaria por Escherichia coli productora de beta lactamasas de espectro extendido (BLEE). Material y métodos: estudio caso control, realizado en clínicas privadas de Lima en ámbito hospitalario. Se incluyeron 30 casos y 30 controles, definiéndose como caso al paciente hospitalizado que cuente con diagnóstico de infección urinaria por urocultivo de E. coli productora de BLEE y como control al paciente hospitalizado sin infección por E. coli BLEE. Se recolectó la información de casos incidentes. Se realizó un análisis bivariado y regresión logística multivariable con las variables que fueron significativas en el análisis bivariado. Resultados: los factores asociados fueron: uso previo de antibióticos OR: 261 (22.5-11017.4), hospitalización previa OR: 4.6 (1.39-16.1), infección urinaria previa OR: 36 (6.9-227.2). Al ajustar por variables potencialmente confusoras mediante regresión logística, se observó que el principal factor asociado con significación estadística fue el uso previo de antibióticos, OR: 97.7 (8.4-1128.3, p<0.000). Conclusión: se encontró evidencia de que el uso previo de antibióticos es un factor de riesgo asociado significativamente a infección urinaria por E. coli BLEE. (Acta Med Colomb 2022; 47. DOI:https://doi.org/10.36104/amc.2022.2131).

Extended Spectrum Beta Lactamase producing Gram negative bacteria - An emerging menace in Neonatal Sepsis.

Introduction: Neonatal sepsis caused by extended spectrum beta lactamase (ESBL) producing Gram negative bacteria (GNB) is associated with significantly high mortality and morbidity. Clinical features and risk factors for such neonatal sepsis can help in identifying it early. Objectives: Aim of the study was to estimate the incidence, risk factors, clinical features and antibiotic sensitivity of GNB and outcomes of ESBL GNB in neonatal sepsis. Methodology: A prospective observational conducted at regional tertiary care health center. Statistical analysis was carried out with SPSS version 23.0. Results: A total of 87 cases of Gram negative neonatal sepsis were included in study. Male: female was 1.7:1. Forty nine (56.3%) isolates were ESBL positive strains. The clinical features in order of frequency were shock, lethargy, sclerema, disseminated intravascular coagulation and severe thrombocytopenia. Out born neonates (p=0.03), late onset sepsis (p=0.05) and mechanical ventilation (p=0.002) were the risk factors for ESBL GNB sepsis. Mortality associated with ESBL sepsis was 26.5%. Carbapenems and Piperacillin + Tazobactum were most sensitive antibiotics and high resistant for cephalosporins was observed. Conclusion: ESBL GNB neonatal sepsis is an emerging threat with high mortality in Neonatal Intensive care unit.

In Silico Modeling and Docking Analysis of CTX-M-5, Cefotaxime-Hydrolyzing ?-Lactamase from Human-Associated Salmonella Typhimurium

Objective: To computationally model the CTX-M-5 ?-lactamase and establish its structure, which is exclusively present in human-associated Salmonella. Methods: The CTX-M-5 aminoacid sequence (Uniprot ID:O65975) of Salmonella enterica subsp. enterica serovar typhimurium was retrieved from UniProt database and subjected to homology modeling using MODELLER 9v7. The homology models were duly validated using RAMPAGE tool by generating Ramachandran plots, ERRAT graphs, and ProSA score. DoGSiteScorer server and ConSurf server were used to detect the cavities, pockets, and clefts to identify conserved amino acid sites in the predicted model. Subsequently, the modeled structure was docked using CLC Drug Discovery Workbench against proven drugs and known inhibitors. Results: Obtained high-quality homology model with 91.7% of the residues in favorable regions in Ramachandran plot and qualified in other quality parameters. Docking studies resulted in a higher dock score for PNK (D-benzylpenicilloic acid) molecule when compared to other reported inhibitors. Conclusion: This in silico study suggests that the compound PNK could be an efficient ligand for CTX-M-5 ?-lactamase and serve as a potent inhibitor of CTX-M-5.

Computer-aided screening for potential inhibitory compounds against a Klebsiella pneumoniae local isolate containing SHV-1 and CTX-M antibiotic resistance genes

Background@#Extended-spectrum beta-lactamases (ESBLs), which allow bacteria to become resistant to commonly used antibiotics against common pathogens such as Klebsiella pneumoniae, are a significant public health concern as their presence severely limits treatment options. Discovery and development of new drug entities are critical to effectively combat infections with these increasingly common antibiotic-resistant variants. @*Objective@#Computational approaches can accelerate and reduce the cost of the discovery phase by screening for inhibitors of “druggable” pathogen enzyme targets in silico. In this study, protein structures of the ESBL enzymes SHV-1 and CTX-M-15 were used as targets in molecular docking experiments to identify potential inhibitors for K. pneumoniae. @*Methodology@#5000 compounds from the Enamine Real HTS compound database were screened in silico for binding to SHV-1 and CTX-M-15. Twenty-six (26) compounds that were identified to have more favorable interactions compared to Avibactam, a known inhibitor of the target proteins, were tested for cytotoxic activities in vivo using Resazurin Microtiter Assay (REMA) against a K. pneumoniae clinical isolate containing both SHV-1 and CTX-M-15 resistance genes. @*Results and Conclusion@#Despite favorable binding energies in in silico screening, most of the compounds exhibited negligible inhibition on the growth of the K. pneumoniae clinical isolate in in vitro assays. This may be attributed to the fact that a phenotypic whole-cell assay, instead of an enzyme-targeted assay, was used for validation. Cell permeability requires a different set of molecular parameters which were not part of the study. Doxorubicin exhibited the highest in vitro bactericidal activity against this strain, which agrees with its known activity against many other bacterial pathogens and may be a promising compound for further lead optimization.

Antimicrobial resistance in Pseudomonas aeruginosa

ABSTRACT@#In recent years, antimicrobial resistance (AMR) has become a global public health concern. The growth of resistant bacteria is increasing dramatically, while the number of new antibiotics accessible is decreasing. This is especially true in the case of Pseudomonas aeruginosa, an important causative agent of healthcare-associated infections. The ability of P. aeruginosa to survive in different environments and on medical devices has made it more resistant to antibiotics. This causes bacteremia in hospitalized patients, ventilator-associated pneumonia, catheter-associated urinary tract infections and wound infections, particularly in patients with severe burns, bed ulcers and immunocompromised individuals. The rise in the AMR rate in both developed and developing countries may be attributed to a number of factors such as variations in the standard health care, large population, awareness about antibiotic resistance, inadequate training on rationale antibiotic usage and inadequate infection control facilities in many hospitals. The emergence of Extensive Drug Resistance (XDR) and Pan Drug Resistance (PDR) among organisms that cause various infections leads to increased treatment costs, morbidity and mortality, leaving no therapeutic options. This review highlights the different mechanisms of antibiotic resistance, including intrinsic and acquired resistance, which are frequently observed in P. aeruginosa.

Pathogenic bacteria spectrum of infectious stones and experience of preventing stone recurrence / 中华泌尿外科杂志

Objective:To investigate the pathogenic bacteria profiles in preoperative urine bacterial cultures of patients with infected kidney stones and use antibacterial drugs to prevent recurrence.Methods:The data of 79 cases with infected kidney stones admitted to the Second Affiliated Hospital of Zhengzhou University from January 2017 to July 2021 were retrospectively analyzed, among whom 29 (36.7%) were male and 50 (63.3%) were female. The age ranged from 17-75 years, with a median age of 49.0 (40, 55) years. Fifteen cases (19.0%) combined hypertension, 13 cases (16.5%) combined diabetes mellitus, and 3 cases (3.8%) combined with cardiovascular disease. Fifty-one cases (64.6%) were diagnosed with cast infectious stones. All patients underwent surgical lithotripsy, and postoperative review of the urological computerized tomography (CT) revealed no residual stones defined as complete lithotripsy, and postoperative oral medication was continued to control infection and prevent stone recurrence. According to post-hospitalization compliance, patients were divided into high and low compliance groups. The high compliance group consisted of patients who returned to the hospital regularly for routine urinalysis and urine bacterial culture after discharge, followed the doctor's prescription for standardized antibacterial drug therapy, and complied with urease inhibitor therapy for ≥6 months. The low compliance group included patients who did not take sensitive antimicrobial drugs regularly and/or were unable to adhere to the medication even after the reduction of vinblastine due to adverse events such as tremor, palpitations, headache, anemia, or gastrointestinal discomfort. The recurrence of stones at 3, 6 and 12 months of follow-up was compared between the two groups.Results:Of the 79 cases in this group, 56(70.9%) were completely clear of stone after surgery. Thirty-three cases (41.8%) presented positive in preoperative urine bacterial culture, and the most common causative organism was Aspergillus oddus in 17 cases (21.5%), followed by Escherichia coli in 8 cases (10.1%) and Klebsiella pneumoniae in 3 cases (3.8%). Among the 17 positive cases of A. oddis, six were positive for ultra broad spectrum β-lactamases (ESBLs), 6/6 were resistant to ampicillin, cefazolin, and cotrimoxazole, 1/6 were resistant to amikacin, cefoxitin, and ticarcillin/stick acid, and none were resistant to imipenem, polymyxin, or aminotrans (0/6 cases). Of the cases, 11 were negative for ESBLs. Ten out of eleven cases were resistant to ampicillin. Furthermore, 8/11 cases were resistant to cefazolin, levofloxacin, ciprofloxacin, and cotrimoxazole and 1/11 were resistant to cefoxitin, cefaclor, furantoin, amikacin, and minocycline, and 0/11 were resistant to imipenem, ticarcillin/stick acid, aminotrans. ESBLs positive strains were resistant to 78.6% of the tested drugs (cefaclor, cefazolin, ceftazidime, furantoin, norfloxacin, levofloxacin, ciprofloxacin, cefoxitin, amoxicillin/rod acid, ticarcillin/rod acid, ampicillin, ceftriaxone, cefotaxime, cefuroxime, cefepime, gentamicin, cotrimoxazole, tobramycin, amikacin, tetracycline, chloramphenicol, and minocycline) at a lower rate of resistance than ESBLs positive strains. Of the eight positive cases of E. coli, seven were ESBLs positive, 7/7 were resistant to ampicillin, cefazolin, cefotaxime, cefuroxime, and cefepime, 1/7 were resistant to cefoxitin and minocycline, and 0/7 were resistant to imipenem, furantoin, or amikacin. One case was ESBLs negative and was resistant to all antimicrobial drugs except for ampicillin. Stone recurrence rates at 3, 6, and 12 months after discharge were 9.1%(4/44) and 31.4%(11/35), 13.6%(6/44), respectively, in the high compliance group, and 60.0%(21/35), 36.4%(16/44), and 71.4% (25/35), respectively, in the low compliance group. All differences were statistically significant.Conclusion:The most common pathogenic bacteria isolated from urine bacterial cultures of patients with infectious stones were A. chimaera, E. coli, and K. pneumoniae. The resistance rate of ESBLs-positive strains to antimicrobial drugs was significantly higher than that of ESBL-negative strains, and the resistance rate of antimicrobial drugs such as β-lactamase inhibitors, cefoxitin, amikacin, and imipenem was low. Combination therapy with standardized sensitive antimicrobial drugs and urease inhibitors significantly reduced the recurrence rate of stones among patients.

Caracterización clínica-microbiológica y factores de riesgo de las bacteriemias por enterobacterias productoras de betalactamasas de espectro extendido en el hospital universitario / Clinical-microbiological characterization and risk factors of bacteremia caused by extended-spectrum beta-lactamase-producing enterobacteria at the university hospital

INTRODUCCIÓN: Las infecciones del torrente sanguíneo se asocian con alta morbi- mortalidad, siendo frecuentemente causadas por enterobacterias, y cuando éstas producen ß-lactamasas de espectro extendido (BLEEs), la morbi-mortalidad, duración internación y costos sanitarios son aún mayores. OBJETIVO: Caracterizar los episodios de bacteriemia por enterobacterias en el Hospital Universitario en un período de 2 años. METODOLOGÍA: Estudio observacional, analítico, casos controles (1:1), con recolección de datos retrospectiva. Población: pacientes ≥18 años atendidos en el Hospital Universitario en período 01/01/2014 - 30/11/2015, con hemocultivo positivo por enterobacteria. Recolección datos clínicos-epidemiológicos: revisión registros médicos. Estudio microbiológico: Identificación y susceptibilidad - equipo automatizado Vitek® 2 system (bioMérieux, Marcy l'Etoile, France). Sensibilidad a fosfomicina: disco-difusión (E. coli) y dilución en agar (resto de las enterobacterias). Ceftazidime-avibactam: disco-difusión. Aislamientos BLEE+ según Vitek: confirmación y caracterización de BLEE: reacción en cadena de la polimerasa (PCR) y secuenciación. Investigación mecanismos transferibles de resistencia a quinolonas (TMQR) qnrB y aac(6')-Ib-cr: PCR. Caracterización molecular enterobacterias BLEE más prevalentes: MultiLocus Sequence Typing (MLST) y Pulsed Field Gel Electrophoresis (PFGE). Análisis casos y controles: I)Factores de riesgo bacteriemia BLEE: Casos - pacientes con bacteriemia por enterobacteria BLEE(+). Controles - pacientes con bacteriemia por enterobacteria BLEE (-) sensible a cefalosporinas tercera generación. II) Factores de riesgo mortalidad intrahospitalaria: Casos - pacientes con mortalidad hospitalaria por cualquier causa. Controles ­ pacientes egresados vivos. Análisis estadístico: paquete estadístico IBM SPSS Statistics 23. Análisis casos y controles: cálculo de odd ratios (OR) e intervalo de confianza al 95% (IC95%). Variables con p ≤0.05 en análisis univariado incluídas en análisis multivariado (regresión logística). Proyecto aprobado por Comité Ética del Hospital de Clínicas y financiado por ANII (FMV_3_2016_1_126580, Fondo María Viña ­ 2016). RESULTADOS: Principales resultados microbiológicos: 174 episodios de bacteriemia y 178 enterobacterias recuperadas, con confirmación molecular de producción BLEE en 41 enterobacterias (23%): 29 Klebsiella pneumoniae, 7 Escherichia coli, 2 Serratia marcescens, 1 Enterobacter cloacae, 1 Citrobacter freundii y 1 Morganella morganii. E. coli enterobacteria más recuperada (n=69), pero K. pneumoniae la enterobacteria BLEE más prevalente (56 aislamientos y 29/56 BLEE+), seguida de E. coli (7/69). Distribución de las enterobacterias BLEE+ según enzima detectada: CTX- M-15: 32 aislamientos, CTX-M-15 + CTX- M-14: 3 aislamientos, CTX-M-2: 3, CTX-M-8: 2, SHV-5: 1. Susceptibilidad enterobacterias BLEE: meropenem 100%, ceftazidime-avibactam 100%, fosfomicina 100%, imipenem 98%, ertapenem 97,6%, colistin 92,7%, amikacina 85,4%, gentamicina 36,6%, tigeciclina 29,3%, piperacilina-tazobactam 26,8%, trimetoprim-sulfametoxazol 19,5%, ciprofloxacina 12,2%. Detección de mecansimos transferibles de resistencia a quinolonas (TMQR) en 33/41 aislamientos (80,5%): aac(6')-Ib-cr: 22 aislamientos, qnrB: 2 aislamientos, y aac(6')-Ib-cr + qnrB: 9 aislamientos. Detección de secuenciotipos "exitosos" en principales enterobacterias BLEE: E. coli ST 73 (1), ST 95(1) y ST 38 (2) y ST 258 en K. pneumoniae (12/29=41,4%). También detección ST 258 en un aislamiento de K. pneumoniae BLEE (-). Principales resultados clínicos ­ epidemiológicos: Se revisaron 98 registros médicos; 60 bacteriemias nosocomiales, 29 comunitarias, 8 asociadas a los cuidados de la salud, 1 sin dato. 41 BLEE(+) y 57 BLEE(-). 80 pacientes vivos al egreso, 17 fallecidos y 1 sin dato. Factores de riesgo bacteriemia BLEE(+) (análisis multivariado) : presencia de dispositivo médico a permanencia previo (p 0,001, OR 55,2, IC 95%5,5-553) ) y bacteriemia no comunitaria (p 0,008 OR 17,4 IC95% 2,1-143). Factores de riesgo mortalidad intrahospitalaria (análisis multivariado): enfermedad hematooncológica o neoplásica (OR 4,687 IC95% 1,207-18,200) y score qPitt ≥2 (OR 10,332 IC95% 2,639-40,442). Antibioticoterapia empírica activa in vitro para la bacteriemia: 10/29(34,5%) en pacientes BLEE(+) y 36/40 BLEE(-) (90%). Se encontró asociación entre bacteriemia BLEE + y recibir antibioticoterapia empírica inactiva (p<0,0001) ; siendo el riesgo de recibir antibioticoterapia empírica inactiva 17 veces mayor en bacteriemias BLEE(+) respecto a BLEE(-). Se encontró que la mediana de la duración de la hospitalización a partir del episodio de bacteriemia es más prolongada en casos BLEE+ que en los controles BLEE- (22,5 versus 14 días, p=0,006). CONCLUSIONES: Enterobacteria BLEE más prevalente K. pneumoniae, y dentro de ella alta prevalencia del clon exitoso de alto riesgo ST 258. Predominio de CTX-M-15, y alta prevalencia (> 80%) de TMQR en aislamientos BLEE. Presencia de BLEE aumenta significativamente el riesgo de recibir antibioticoterapia empírica inactiva. Necesidad de mantener vigilancia de perfiles de susceptibilidad y clones circulantes y considerar posibles factores de riesgo al momento se seleccionar antibioticoterapia empírica.

BACKGROUND: Bloodstream infections are associated with high morbidity and mortality, being frequently caused by Enterobacteriaceae, and when they produce extended spectrum ß-lactamases (ESBL), morbidity, mortality and healthcare costs are even higher. OBJECTIVE: We aimed to characterize Enterobacteriaceae bacteremia episodes at the "Hospital de Clínicas", in a 2 years period. METHODS: Observational, analytical study, case-controls (1: 1), with retrospective data collection. Population: ≥18 years old patients attended at the "Hospital de Clínicas" between 01/01/2014 and 11/30/2015, with Enterobacteriaceae recovered from blood culture. Collection of clinical-epidemiological data: review of medical records. Microbiological study: identification and susceptibility: automated system Vitek® 2 (bioMérieux, Marcy l'Etoile, France). Susceptibility to fosfomycin: disc-diffusion (E. coli) and agar dilution (others Enterobacterales). Ceftazidime-avibactam: disc-diffusion. ESBL (+) isolates according to Vitek: ESBL confirmation and characterization by Polymerase Chain Reaction (PCR) and sequencing. Investigation of transferable mechanisms of quinolone resistance (TMQR) qnrB and aac (6 ')- Ib-cr: PCR. Molecular characterization of the most prevalent ESBL enterobacterales: MultiLocus Sequence Typing (MLST) and Pulsed Field Gel Electrophoresis (PFGE). Case-control analysis: I) ESBL bacteremia risk factors: Cases - patients with bacteremia by an ESBL-producing enterobacteria. Controls - patients with third generation cephalosporin susceptible enterobacteria, not ESBL-producing. II) In-hospital mortality risk factors: Cases - patients with in-hospital mortality from any cause. Controls - patients discharged alive. Statistical analysis: IBM SPSS Statistics 23 statistical package. Case-control analysis: calculation of odd ratios (OR) and 95% confidence interval (95% CI). Variables with p ≤0.05 in univariate analysis were included in multivariate analysis (logistic regression). Project approved by the Hospital de Clinicas Ethics Committee and financed by ANII (FMV_3_2016_1_126580, María Viña Fund - 2016). RESULTS: Main microbiological results: 174 bacteremia episodes and 178 enterobacterales recovered. ESBL production confirmated in 41 isolates (23%): 29 Klebsiella pneumoniae, 7 Escherichia coli, 2 Serratia marcescens, 1 Enterobacter cloacae, 1 Citrobacter freundii y 1 Morganella morganii.E. coli was the most recovered enterobacteria (n = 69), but K. pneumoniae was the most prevalent ESBL producing specie (56 isolates and 29/56 ESBL +), followed by E. coli (7/69). Distribution of ESBL producing enterobacterales according to enzyme detected: CTX- M-15: 32 isolates, CTX-M-15 + CTX-M-14: 3 isoaltes, CTX-M-2: 3, CTX-M-8: 2, SHV-5: 1. Antibiotic susceptibility in ESBL producers: meropenem 100%, ceftazidime-avibactam 100%, fosfomycin 100%, imipenem 98%, ertapenem 97,6%, colistin 92,7%, amikacin 85,4%, gentamicin 36,6%, tigecycline 29,3%, piperacillin-tazobactam 26,8%, trimethroprim sulfamethoxazole 19,5%, ciprofloxacin 12,2%. Detection of TMQR in 33/41 isolates (80.5%): aac(6')-Ib-cr: 22 isolates, qnrB: 2 isolates, and aac(6')Ib-cr + qnrb: 9 isolates. We detected "successful" sequence types within E. coli ESBL producing: ST 73 (1 isolate), ST 95 (1) and ST 38 (2) and a high prevalence of ST 258 among K. pneumoniae isolates (12/29 = 41.4%). ST 258 was also detected in one ESBL(-) K. pneumoniae isolate. Main clinical-epidemiological results: 98 medical records were reviewed; 60 bacteremia episodes were classified as nosomial, 29 as community acquired, 8 health care associated, and for one episode, data was insufficient for its classification. 41 were ESBL(+) and 57 ESBL(-). 80 patients alive at discharge, 17 deceased and 1 without data. Risk factors for ESBL bacteremia according to multivariate analysis were: use of medical device prior to hospitalization (OR = 50.226, 95% CI 4.367 - 577.721) and non-community bacteremia (OR 12.052, 95% CI 1.350-107.605). In-hospital mortality risk factors (multivariate analysis): hemato-oncological or neoplasic disease (OR 4,687 95% CI 1,207-18,200) and qPitt score ≥2 (OR 10,332 95% CI 2,639-40,442). The empirical antibiotic therapy was active according to the susceptibility test in 10/29 (34,5%) patients with ESBL (+) bacteremia and in 36/40 patients with ESBL (-) (90%). Presence of ESBL was found to be associated with inactive empirical antibiotic therapy (p<0.0001), and risk for receiving inactive empirical antibiotic therapy was 17 times higher in ESBL (+) compared to ESBL (-). The mean length of hospital stay after the onset of bacteraemia was longer in the cases of ESBL producers than in the cases of non-ESBL producers ( 22,5 vs. 14 days; P=0.006). CONCLUSIONS: K. pneumoniae was the most prevalent ESBL producing specie, and within it we found a high prevalence of the successful high-risk clone ST258. CTX-M-15 was the main ESBL detected and we found high prevalence (80%) of TMQR among ESBL(+). Presence of ESBL significantly increases the risk of receiving inactive empirical antibiotic therapy. Need to maintain surveillance of susceptibility profiles and circulating clones and to take into account possible risk factors when selecting empirical antibiotic therapy.

Detección de ß-lactamasas de espectro extendido en Escherichia coli aisladas de ecosistemas dulceacuícolas de La Habana / Detection of extended-spectrum ß;-lactamases in Escherichia coli isolated from freshwater ecosystems in Havana

Introducción: Las cepas de Escherichia coli productoras de β-lactamasas de espectro extendido son patógenos multirresistentes y una de las bacterias que más contribuyen con la resistencia antibiótica bacteriana en la clínica. Sin embargo, se aíslan cada vez con más frecuencia de ambientes naturales, tales como los ecosistemas acuáticos en los cuales se emplea como un indicador de contaminación fecal. Objetivo: Evaluar la susceptibilidad a los antibióticos y la producción de enzimas ß-lactamasas de espectro extendido de aislados de Escherichia coli procedentes de ecosistemas dulceacuícolas de La Habana. Métodos: Se analizaron 43 aislados de E. coli provenientes de los ríos Almendares, Quibú y Luyanó de La Habana. Se determinó la susceptibilidad a 18 antibióticos y la producción fenotípica de ß-lactamasas de espectro extendido según las normas del Instituto de Estándares para el Laboratorio Clínico. La detección molecular de las enzimas se realizó mediante reacción en cadena de la polimerasa. Se calculó el índice de multirresistencia a los antibióticos y los patrones de resistencia de cada aislado de E. coli- ß-lactamasas de espectro extendido. Resultados: El 65 por ciento de los aislados de E. coli fueron resistentes al menos a un antibiótico y el 35 por ciento fueron sensibles a todos los antibióticos. El fenotipo ß-lactamasas de espectro extendido fue detectado en siete aislados; de estos, cuatro fueron portadores del gen bla CTX-M-1 y tres presentaron bla TEM. El 37 por ciento de los aislados de E. coli mostraron valores de índices de multirresistencia a los antibióticos menores que 0,22; el 16 por ciento de 0,22; el 9,3 por ciento mayor que 0,5; y el 5 por ciento mayor que 0,7. Los aislados de E. coli-BLEE mostraron corresistencia a las familias de las tetraciclinas, quinolonas, aminoglucósidos y macrólidos. Conclusiones: La presencia de aislados ambientales multirresistentes de E. coli productores de ß-lactamasas de espectro extendido en ecosistemas dulceacuícolas de La Habana destaca la necesidad de implementar estrategias de control para prevenir la diseminación de estos aislados en los ambientes naturales(AU)

Introduction: Extended-spectrum β-lactamase-producing Escherichia coli strains are multiresistant pathogens and one of the bacteria contributing most greatly to bacterial antibiotic resistance in clinical practice. However, they are increasingly isolated from natural environments, such as aquatic ecosystems, where they are used as fecal pollution indicators. Objective: Evaluate antibiotic susceptibility and extended-spectrum ß-lactamase enzyme production in Escherichia coli isolates from freshwater ecosystems in Havana. Methods: An analysis was conducted of 43 E. coli isolates from the rivers Almendares, Quibú and Luyanó in Havana. Determination was made of susceptibility to 18 antibiotics and phenotypic production of extended-spectrum ß-lactamases according to standards from the Clinical and Laboratory Standards Institute. Molecular detection of the enzymes was performed by polymerase chain reaction. Estimation was carried out of the antibiotic multiresistance index and the resistance patterns of each extended-spectrum E. coli ß-lactamase isolate. Results: Of the E. coli isolates studied, 65 percent were resistant to at least one antibiotic, whereas 35 percent were sensitive to all antibiotics. The extended-spectrum ß-lactamase phenotype was detected in seven isolates, of which four were carriers of the gene bla CTX-M-1 and three contained bla TEM. 37 percent of the E. coli isolates displayed antibiotic multiresistance index values below 0.22, 16 percent of 0.22, 9.3 percent above 0.5 and 5 percent above 0.7. ESBL E. coli isolates displayed co-resistance to the families tetracyclines, quinolones, aminoglycosides and macrolides. Conclusions: The presence of multiresistant extended-spectrum ß-lactamase-producing environmental E. coli isolates in Havana freshwater ecosystems highlights the need to implement control strategies aimed at preventing the spread of these isolates in natural environments(AU)

Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido en un hospital de La Habana

RESUMEN Introducción: En microorganismos gramnegativos la producción de enzimas betalactamasas es el mecanismo más común de resistencia. Las de espectro extendido constituyen un grupo importante por su capacidad de inactivar las cefalosporinas de tercera y cuarta generación y el aztreonam. Su detección es vital para indicar el tratamiento óptimo y las medidas de aislamiento que eviten la dispersión de los microorganismos que las portan. Objetivos: Determinar la incidencia y principales características de los aislados de Escherichiacoli y Klebsiellapneumoniae productores de betalactamasas de espectro extendido en muestras no urogenitales. Métodos: Estudio transversal realizado en el hospital "Salvador Allende" durante el año 2017. Se determinó la frecuencia de Escherichia coli y Klebsiella pneumoniae productoras de betalactamasas de espectro extendido, su procedencia según servicio del hospital, tipo de muestra clínica, y su sensibilidad antimicrobiana. La identificación de betalactamasas de espectro extendido se hizo por el método de doble disco de Jarlier. Resultados: Fueron productores de betalactamasas de espectro extendido 46 y 50 % de aislados de Escherichia coli y Klebsiella pneumoniae, respectivamente. La mayoría provenían de muestras de las salas del Instituto de Angiología, el antimicrobiano con mayor efectividad fue el meropenem, la sensibilidad al resto de los antimicrobianos estuvo por debajo de 80 % y no hubo aislados sensibles a las cefalosporinas de tercera generación. Conclusiones: Se demuestra una alta incidencia de aislados de Escherichia coli y Klebsiella pneumoniae productores de betalactamasas de espectro extendido en el Hospital "Salvador Allende" de La Habana, más marcada en las salas del Instituto de Angiología y en muestras de piel.

ABSTRACT Introduction: Beta-lactamase production is the most common resistance mechanism in gram-negative microorganisms. Extended-spectrum beta-lactamases are an important group of enzymes capable of inactivating third- and fourth-generation cephalosporins and aztreonam. Their detection is important to indicate the optimum treatment as well as isolation measures aimed at preventing the spread of carrier microorganisms. Objectives: Determine the incidence and main characteristics of isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae from non-urogenital samples. Methods: A cross-sectional study was conducted at Salvador Allende hospital during the year 2017. Determination was made of the frequency of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, their origin by hospital service, the type of clinical sample and their antimicrobial sensitivity. Identification of extended-spectrum beta-lactamases was based on the Jarlier double disc method. Results: Of the total Escherichia coli and Klebsiella pneumoniae isolates studied, 46% and 50%, respectively, were extended-spectrum beta-lactamase producers. Most had been obtained from samples taken in wards of the Institute of Angiology; the most effective antimicrobial was meropenem; sensitivity to the remaining antimicrobials was below 80%; no isolates were sensitive to third-generation cephalosporins. Conclusions: A high incidence was found of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates at Salvador Allende Hospital in Havana, more noticeably in Institute of Angiology wards and skin samples.

Factores de riesgo para infección del tracto urinario por microorganismos productores de betalactamasas de espectro extendido en niños en Huancayo, Perú

Introducción: La infección del tracto urinario en los niños es una de las infecciones bacterianas más frecuentes con una alta tasa de recurrencia. Objetivo: Determinar los factores de riesgo para infección del tracto urinario adquirida en la comunidad por microorganismos productores de betalactamasas de espectro extendido en niños en Huancayo, Perú. Métodos: Estudio de tipo analítico con diseño de casos y controles. Se estudiaron 220 niños entre el mes de nacido hasta 13 años de edad, ingresados en el hospital nacional "Ramiro Priale Priale" con el diagnóstico de infección del tracto urinario durante el año 2019. Se distribuyeron en dos grupos (40 casos y 80 controles). Para cada paciente se llenó un cuestionario con las variables de interés y se realizó la comparación entre los grupos. Se realizó el análisis multivariado considerando significativo un valor de p< 0,05. Resultados: La frecuencia de infección del tracto urinario causada por microorganismos productores de betalactamasas de espectro extendido es de 18,18 %. En los casos la edad predominante está entre 1 y 3 años con 42,5 %, sexo femenino con 62,5 %, la bacteria predominante es: Escherichia coli en 85,0 %. Durante el análisis multivariado la presencia de infección del tracto urinario complicada tuvo OR 18,62 y p= 0,000 y la recurrente OR 12,98 y p= 0,004, ambas estadísticamente significativas para el desenlace de esta infección en los niños. Conclusión: Los factores de riesgo para infección del tracto urinario adquirida en la comunidad por microorganismos productores de betalactamasas de espectro extendido en niños son: infección del tracto urinario complicada y la recurrente.

Introduction: Urinary tract infection in children is one of the most frequent bacterial infections with a high rate of recurrence. Objective: Determine the risk factors for community-acquired urinary tract infection by microorganisms producing extended-spectrum beta-lactamases in children of Huancayo, Peru. Methods: Analytical study with case-control design. 220 children from one month to 13 years of age were studied, whom were admitted to "Ramiro Priale Priale" National Hospital with the diagnosis of urinary tract infection during the year 2019. They were distributed in two groups (40 cases and 80 controls). For each patient, a questionnaire was completed with the variables of interest, and the comparison between the groups was made. The multivariate analysis was performed considering significant a value of p< 0.05. Results: The frequency of urinary tract infection caused by microorganisms producing extended-spectrum beta-lactamases is 18.18%. In the cases, the predominant age is between 1 and 3 years with 42.5%, female sex with 62.5%, the predominant bacterium is: Escherichia coli in 85.0%. During the multivariate analysis, the presence of complicated urinary tract infection had OR 18.62 and p= 0.000 and recurrent OR 12.98 and p= 0.004, both statistically significant for the outcome of this infection in children. Conclusion: The risk factors for community-acquired urinary tract infection by microorganisms producing extended-spectrum beta-lactamases in children are complicated and recurrent urinary tract infections.

Isolation and Molecular Characterization of Extended Spectrum Beta Lactamase Producing Escherichia coli from Milk

Milk plays a major role as a source of nutrition in the diet but contaminated milk can be a source of harmful bacteria. Escherichia coli is opportunistic pathogen and is responsible for a wide range of infections. The prevalence of pathogenic multi-drug resistant extended-spectrum β-lactamase (ESBL)-producing E. coli is increasing and becoming a global concern. A study was carried out to isolate ESBL producing E. coli from 150 milk samples from Anand and around villages. Total 94(62.66%) samples were found positive as E. coli by isolation on MacConkey and Eosin Methylene Blue agar which were confirmed by primary & biochemical tests including Gram’s staining. Antibiotic sensitivity test (ABST) was performed against 6 antibiotics and isolates found resistant to Aztrionem: 58(61%), Cefoxitin: 20(21%), Ceftriaxone: 56(59%), Ceftazidime: 62(65%), Cefpodoxime: 34(44.73%) & Ceftazidime + Clavulanic acid: 8(8.5%). A total 34(36.17%) ESBL producing E. coli were phenotypically confirmed by ABST and Epsilometer test. Genotypic confirmation of 34 isolates was done by PCR and isolates found positive for bla CTX M-3 gene: 18(52.94%), bla CTX M-9 gene 6(17.64%), bla SHV gene: 5(14.70%) and bla TEM gene: 5(14.70%). In summary, analyzed milk samples were found to have a health risk for consumers due to contamination by ESBL producing E. coli, their pathogenicity and treatment failure as a result of antibiotic resistance

Prevalence and Risk Factors for Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae Colonization in Intensive Care Units

Active surveillance culture (ASC) can help detect hidden reservoirs, but the routine use of ASC for extended spectrum β-lactamase-producing Enterobacteriaceae is controversial in an endemic situation. We aimed to determine the prevalence and risk factors of extended spectrum β-lactamase-producing Klebsiella pneumoniae (EBSL-Kpn) colonization among intensive care unit (ICU)-admitted patients. Prospective screening of ESBL-Kpn colonization was performed for ICU-admitted patients within 48 hours for two months. A perirectal swab sample was inoculated on MacConkey agar supplemented with 2 µg/mL ceftazidime. ESBL genotype was determined by PCR-sequencing, and clonal relatedness was evaluated by pulsed-field gel electrophoresis (PFGE). The risk factors of ESBL-Kpn colonization were evaluated. The ESBL-Kpn colonization rate among the 281 patients at ICU admission was 6.4% (18/281), and bla(CTX-M-15) was detected in all isolates. ESBL producers also showed resistance to fluoroquinolone (38.9%, 7/18). All isolates had the same ESBL genotype (bla(CTX-M-15)) and a highly clustered PFGE pattern, suggesting cross-transmission without a documented outbreak. In univariate analysis, the risk factor for ESBL-Kpn colonization over the control was the length of hospital stay (odds ratio=1.062; P=0.019). Routine use of ASC could help control endemic ESBL–Kpn for ICU patients.